Literature DB >> 11238232

Dose-dependent circulating immunoglobulin A antibody-secreting cell and serum antibody responses in Swedish volunteers to an oral inactivated enterotoxigenic Escherichia coli vaccine.

M Jertborn1, C Ahrén, A M Svennerholm.   

Abstract

The immunogenicity of different preparations of an oral inactivated enterotoxigenic Escherichia coli (ETEC) vaccine was evaluated in Swedish volunteers previously unexposed to ETEC infection. The vaccine preparations consisted of recombinant cholera toxin B subunit (CTB) and various amounts of formalin-killed whole bacteria expressing the most prevalent colonization factor antigens (CFAs). Significant immunoglobulin A (IgA) antibody-secreting cell (ASC) responses against CTB and the various CFA components were seen in a majority of volunteers after two doses of ETEC vaccine independent of the vaccine lot given. The IgA ASC responses against CTB were significantly higher after the second than after the first immunization, whereas the CFA-specific IgA ASC responses were almost comparable after the first and second doses of ETEC vaccine. Two immunizations with one-third of a full dose of CFA-ETEC bacteria induced lower frequencies of IgA ASC responses against all the different CFAs than two full vaccine doses, i.e., 63 versus 80% for CFA/I, 56 versus 70% for CS1, 31 versus 65% for CS2, and 56 versus 75% for CS4. The proportion of vaccinees responding with rises in the titer of serum IgA antibody against the various CFA antigens was also lower after immunization with the reduced dose of CFA-ETEC bacteria. These findings suggest that measurements of circulating IgA ASCs can be used not only for qualitative but also for quantitative assessments of the immunogenicity of individual fimbrial antigens in various preparations of ETEC vaccine.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11238232      PMCID: PMC96073          DOI: 10.1128/CDLI.8.2.424-428.2001

Source DB:  PubMed          Journal:  Clin Diagn Lab Immunol        ISSN: 1071-412X


  22 in total

1.  Safety and immunogenicity of an oral, inactivated enterotoxigenic Escherichia coli plus cholera toxin B subunit vaccine in Bangladeshi adults and children.

Authors:  F Qadri; C Wennerâs; F Ahmed; M Asaduzzaman; D Saha; M J Albert; R B Sack; A Svennerholm
Journal:  Vaccine       Date:  2000-06-01       Impact factor: 3.641

2.  Safety and immunogenicity of the live oral auxotrophic Shigella flexneri SFL124 in volunteers.

Authors:  A Li; T Pál; U Forsum; A A Lindberg
Journal:  Vaccine       Date:  1992       Impact factor: 3.641

3.  Prevention of travellers' diarrhoea by oral B-subunit/whole-cell cholera vaccine.

Authors:  H Peltola; A Siitonen; H Kyrönseppä; I Simula; L Mattila; P Oksanen; M J Kataja; M Cadoz
Journal:  Lancet       Date:  1991-11-23       Impact factor: 79.321

4.  Active immunity is seen as a reduction in the cell response to oral live vaccine.

Authors:  A Kantele; J M Kantele; H Arvilommi; P H Mäkelä
Journal:  Vaccine       Date:  1991-06       Impact factor: 3.641

Review 5.  Development of oral vaccines against enterotoxinogenic Escherichia coli diarrhoea.

Authors:  A M Svennerholm; J Holmgren; D A Sack
Journal:  Vaccine       Date:  1989-06       Impact factor: 3.641

6.  Saliva, breast milk, and serum antibody responses as indirect measures of intestinal immunity after oral cholera vaccination or natural disease.

Authors:  M Jertborn; A M Svennerholm; J Holmgren
Journal:  J Clin Microbiol       Date:  1986-08       Impact factor: 5.948

7.  A solid-phase enzyme-linked immunospot (ELISPOT) assay for enumeration of specific antibody-secreting cells.

Authors:  C C Czerkinsky; L A Nilsson; H Nygren; O Ouchterlony; A Tarkowski
Journal:  J Immunol Methods       Date:  1983-12-16       Impact factor: 2.303

8.  Oral, inactivated, whole cell enterotoxigenic Escherichia coli plus cholera toxin B subunit vaccine: results of the initial evaluation in children. PRIDE Study Group.

Authors:  S J Savarino; E R Hall; S Bassily; F M Brown; F Youssef; T F Wierzba; L Peruski; N A El-Masry; M Safwat; M Rao; H El Mohamady; R Abu-Elyazeed; A Naficy; A M Svennerholm; M Jertborn; Y J Lee; J D Clemens
Journal:  J Infect Dis       Date:  1999-01       Impact factor: 5.226

9.  Cross-protection by B subunit-whole cell cholera vaccine against diarrhea associated with heat-labile toxin-producing enterotoxigenic Escherichia coli: results of a large-scale field trial.

Authors:  J D Clemens; D A Sack; J R Harris; J Chakraborty; P K Neogy; B Stanton; N Huda; M U Khan; B A Kay; M R Khan
Journal:  J Infect Dis       Date:  1988-08       Impact factor: 5.226

10.  Serologic differentiation between antitoxin responses to infection with Vibrio cholerae and enterotoxin-producing Escherichia coli.

Authors:  A M Svennerholm; J Holmgren; R Black; M Levine; M Merson
Journal:  J Infect Dis       Date:  1983-03       Impact factor: 5.226

View more
  9 in total

1.  Oral immunization with a recombinant malaria protein induces conformational antibodies and protects mice against lethal malaria.

Authors:  Lina Wang; Lukasz Kedzierski; Steven L Wesselingh; Ross L Coppel
Journal:  Infect Immun       Date:  2003-05       Impact factor: 3.441

2.  Comparative safety and immunogenicity of two attenuated enterotoxigenic Escherichia coli vaccine strains in healthy adults.

Authors:  Robin McKenzie; A Louis Bourgeois; Fayette Engstrom; Eric Hall; H Sunny Chang; Joseph G Gomes; Jennifer L Kyle; Fred Cassels; Arthur K Turner; Roger Randall; Michael Darsley; Cynthia Lee; Philip Bedford; Janet Shimko; David A Sack
Journal:  Infect Immun       Date:  2006-02       Impact factor: 3.441

3.  Construction and phase I clinical evaluation of the safety and immunogenicity of a candidate enterotoxigenic Escherichia coli vaccine strain expressing colonization factor antigen CFA/I.

Authors:  Arthur K Turner; Juliet C Beavis; Jonathan C Stephens; Judith Greenwood; Cornelia Gewert; Nicola Thomas; Alison Deary; Gabriella Casula; Alexandra Daley; Paul Kelly; Roger Randall; Michael J Darsley
Journal:  Infect Immun       Date:  2006-02       Impact factor: 3.441

4.  Mucosal and systemic immune responses in patients with diarrhea due to CS6-expressing enterotoxigenic Escherichia coli.

Authors:  Firdausi Qadri; Tanvir Ahmed; Firoz Ahmed; M Saruar Bhuiyan; Mohammad Golam Mostofa; Frederick J Cassels; Anna Helander; Ann-Mari Svennerholm
Journal:  Infect Immun       Date:  2007-02-12       Impact factor: 3.441

Review 5.  From cholera to enterotoxigenic Escherichia coli (ETEC) vaccine development.

Authors:  Ann-Mari Svennerholm
Journal:  Indian J Med Res       Date:  2011-02       Impact factor: 2.375

6.  Antigen-specific memory B-cell responses to enterotoxigenic Escherichia coli infection in Bangladeshi adults.

Authors:  Mohammad Murshid Alam; Amena Aktar; Sadia Afrin; Mohammad Arif Rahman; Sarmin Aktar; Taher Uddin; M Arifur Rahman; Deena Al Mahbuba; Fahima Chowdhury; Ashraful Islam Khan; Taufiqur Rahman Bhuiyan; Yasmin Ara Begum; Edward T Ryan; Stephen B Calderwood; Ann-Mari Svennerholm; Firdausi Qadri
Journal:  PLoS Negl Trop Dis       Date:  2014-04-24

7.  Evaluation of the safety and immunogenicity of the oral inactivated multivalent enterotoxigenic Escherichia coli vaccine ETVAX in Bangladeshi adults in a double-blind, randomized, placebo-controlled Phase I trial using electrochemiluminescence and ELISA assays for immunogenicity analyses.

Authors:  Marjahan Akhtar; Mohiul I Chowdhury; Taufiqur R Bhuiyan; Joanna Kaim; Tasnuva Ahmed; Tanzeem A Rafique; Arifuzzaman Khan; Sadia I A Rahman; Farhana Khanam; Yasmin A Begum; Mir Z Sharif; Laila N Islam; Nils Carlin; Nicole Maier; Alan Fix; Thomas F Wierzba; Richard I Walker; A Louis Bourgeois; Ann-Mari Svennerholm; Firdausi Qadri; Anna Lundgren
Journal:  Vaccine       Date:  2018-11-22       Impact factor: 3.641

8.  Safety and immunogenicity of a prototype enterotoxigenic Escherichia coli vaccine administered transcutaneously.

Authors:  Fernando Güereña-Burgueño; Eric R Hall; David N Taylor; Frederick J Cassels; Daniel A Scott; Marcia K Wolf; Zachary J Roberts; Galina V Nesterova; Carl R Alving; Gregory M Glenn
Journal:  Infect Immun       Date:  2002-04       Impact factor: 3.441

9.  Safety and immunogenicity of the oral, inactivated, enterotoxigenic Escherichia coli vaccine ETVAX in Bangladeshi children and infants: a double-blind, randomised, placebo-controlled phase 1/2 trial.

Authors:  Firdausi Qadri; Marjahan Akhtar; Taufiqur R Bhuiyan; Mohiul I Chowdhury; Tasnuva Ahmed; Tanzeem A Rafique; Arifuzzaman Khan; Sadia I A Rahman; Farhana Khanam; Anna Lundgren; Gudrun Wiklund; Joanna Kaim; Madeleine Löfstrand; Nils Carlin; A Louis Bourgeois; Nicole Maier; Alan Fix; Thomas Wierzba; Richard I Walker; Ann-Mari Svennerholm
Journal:  Lancet Infect Dis       Date:  2019-11-19       Impact factor: 25.071

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.